Evidence map›Paper›PMID 37499728›Full record

ArticleActa biomaterialia2023

Broadly neutralizing antibodies consistently trap HIV-1 in fresh cervicovaginal mucus from select individuals.

Alison Schaefer, Bing Yang, Holly A Schroeder, Dimple Harit, Mike S Humphry, Jacques Ravel, Samuel K Lai

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Alison SchaeferUNC/NCSU Joint Department of Biomedical Engineering, Chapel Hill, NC 27519, USA.
Bing YangDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27519,USA.
Holly A SchroederDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27519,USA.
Dimple HaritDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27519,USA.
Mike S HumphryDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jacques RavelDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Samuel K LaiUNC/NCSU Joint Department of Biomedical Engineering, Chapel Hill, NC 27519, USA; Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27519,USA; Department of Microbiology & Immunology; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: lai@unc.edu.
University of North Carolina at Chapel Hill · USUniversity of Maryland, Baltimore · USUNC/NCSU Joint Department of Biomedical Engineering · US

Funding

Serologic Biomarkers of Human Sexually Transmitted Infection and DiseaseU19AI084044 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI TETTELIN, HERVE S · 2009 to 2018
$22.8M
Vaginal mAB Delivery SystemsU19AI096398 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ANDERSON, DEBORAH J, MOENCH, THOMAS RAY · 2011 to 2016
$15.0M
Trapping HIV in mucus with IgG antibodiesR21AI093242 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAI, SAMUEL · 2011 to 2012
$403k
NIAID NIH HHS R21 AI093242NIAID NIH HHS U19 AI084044NIAID NIH HHS U19 AI096398
6 · The paper itself

Abstract

In addition to direct neutralization and other classical effector functions, IgG possesses a little recognized and thus under-utilized effector function at mucosal surfaces: Fc-mucin bonds enable IgG to trap viruses in mucus. Due to the paucity of envelope glycoproteins that limits the number of IgG that can bind HIV, it remains poorly understood whether IgG-mucin interactions can effectively immobilize HIV in human cervicovaginal mucus (CVM). Here, we obtained 54 fresh, undiluted CVM specimens from 17 different women, and employed high-resolution multiple particle tracking to quantify the mobility of fluorescent HIV virus-like-particles in CVM treated with various HIV-specific IgG. We observed consistent and effective trapping of HIV by broadly neutralizing antibodies (VRC01, PGT121, and 2F5) in a subset of women. While trapping efficacy was not affected by the menstrual cycle, it was positively correlated with appreciable L. Crispatus populations in the microbiome, and negatively correlated with appreciable L. Iners or G. Vaginalis populations. Our work demonstrates for the first time that IgG-mucin crosslinking is capable of reinforcing the mucosal barrier against HIV, and motivates further investigation of passive immunization against vaginal transmission of STIs. STATEMENT OF SIGNIFICANCE: HIV transmission in women primarily occurs vaginally, yet the 3-way interactions between mucins and HIV virions mediated by HIV-binding antibodies in cervicovaginal mucus (CVM) is not well understood. While IgG-Fc possess weak affinity to mucins that trap virus/IgG complexes in mucus, the effectiveness against HIV remains unclear, due to the low number of virion-bound IgG. Here, we discovered that IgG can trap HIV consistently in CVM from select individuals regardless of their birth control status or menstrual cycle phase. IgG-mediated trapping of HIV was moderately associated with microbiome composition. These results suggest that IgG-mucin interactions could potentially reduce HIV transmission and highlight the importance of mucosal secretions in antibody-mediated prevention of HIV and other sexually transmitted infections.

Indexed as

HIV-1HIV InfectionsBroadly Neutralizing AntibodiesCervix UteriFemaleHumansImmunoglobulin GMucinsMucusBroadly Neutralizing AntibodiesImmunoglobulin GMucinsAntibodiesDiffusionHIVIgGMucosal immunologyPassive immunization

Identifiers

PMID37499728
PMCPMC10619885
OpenAlexW4385330294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.